Search results
Showing 106 to 120 of 127 results for bacterial infections
Developmental follow-up of children and young people born preterm (NG72)
This guideline covers the developmental follow-up of babies, children and young people under 18 years who were born preterm (before 37+0 weeks of pregnancy). It explains the risk of different developmental problems and disorders, and specifies what extra assessments and support children born preterm might need during their growth and development.
QuickChange Incontinence Wrap for urinary incontinence in men (MIB237)
NICE has developed a medtech innovation briefing (MIB) on QuickChange Incontinence Wrap for urinary incontinence in men .
stopped working and needs to be removed, or there are concerns about line infection). The committee did not define how long parenteral...
This guideline covers parenteral nutrition (intravenous feeding) for babies born preterm, up to 28 days after their due birth date and babies born at term, up to 28 days after their birth. Parenteral nutrition is often needed by preterm babies, critically ill babies, and babies who need surgery.
Evidence-based recommendations on the VAC Veraflo Therapy system for acute infected or chronic wounds that are failing to heal.
NICE has developed a Medtech Innovation Briefing (MIB) on Oxyzyme and Iodozyme 2-layer hydrogel wound dressings with iodine for treating chronic wounds
This evidence summary has been updated and replaced by NICE antimicrobial health technology evaluation guidance on cefiderocol for treating severe drug-resistant gram-negative bacterial infections.
This evidence summary has been updated and replaced by NICE antimicrobial health technology evaluation guidance on ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections.
Antimicrobial Products Subscription Model We urgently need new drugs for infections that are resistant to existing treatments. But...
Urinary tract infection (catheter-associated): antimicrobial prescribing (NG113)
This guideline sets out an antimicrobial prescribing strategy for catheter-associated urinary tract infection in children, young people and adults. It aims to optimise antibiotic use and reduce antibiotic resistance.
Rituximab for the first-line treatment of chronic lymphocytic leukaemia (TA174)
Evidence-based recommendations on rituximab for untreated chronic lymphocytic leukaemia in adults.
Evidence-based recommendations on certolizumab pegol (Cimzia) for treating severe active rheumatoid arthritis in adults who have had a tumour necrosis factor-alpha inhibitor.
hospital-acquired pneumonia to guide antibiotic therapy. Hospital-acquired infections can be caused by highly resistant pathogens that...
Cytokine adsorption devices for treating respiratory failure in people with COVID-19 (MIB217)
NICE has developed a medtech innovation briefing (MIB) on cytokine adsorption devices for treating respiratory failure in people with COVID-19 .
Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia (TA193)
Evidence-based recommendations on rituximab for treating relapsed or refractory chronic lymphocytic leukaemia in adults.